Non-invasive prostate cancer test may reduce biopsies

The French firm bioMérieux and ProteoSys, based in Mainz, Germany, have signed a license and development agreement for Annexin 3 to be used to develop a urine-based, confirmatory diagnostic test for prostate cancer.

After a research phase, the new test should be developed on the VIDAS platform.
Annexin 3, also known as ANXA 3, was discovered by ProteoSys, which specialises in cell biology and proteomics. Studies have shown that ANXA 3 quantification in urine is a novel, non-invasive test with high specificity for prostate cancer. Today, when the levels of prostate specific antigen (PSA) are in the uninformative ‘grey zone’, a biopsy is used to provide definitive diagnosis. The ANXA 3 test would be used to provide better identification of patients with a high probability of prostate cancer, thereby reducing the number of unnecessary biopsies.
After the first research phase at bioMérieux, a diagnostic test for the VIDAS platform will be developed. While the confirmatory diagnostic application on VIDAS will be the initial focus, bioMérieux is also considering the development of treatment decision and prognostic applications for ANXA 3.

28.10.2008

More on the subject:

Related articles

Photo

Article • Advances in mobile monitoring

Wearable technology transforms laboratory medicine

Remote monitoring via microfluidic platforms, AI-assisted sensor systems, and more: Attendees of the Labmed Forum at Medica saw impressive examples on how wearable technology is becoming a…

Photo

News • Staining instrument family

New pathology lab solutions debut at ECP 2025

Agilent Technologies Inc. announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of…

Photo

News • Patient involvement enables research

Tumor vesicles as a promising biomarker for early cancer detection

Tumor vesicles may serve as early indicators of cancer and help monitor the effectiveness of treatments. Now, researchers discovered a new way to detect these vesicles.

Related products

Subscribe to Newsletter